Home › Research › Caregiving
Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations
Yates PA, Villemagne VL, Ellis KA, Desmond PM, Masters CL, Rowe CC.. Frontiers in neurology, 2014-01-06
Topic: Risk, prevention and care in population studies
Plain-language summary
Cerebral microbleeds (microbleeds) are small, punctuate hypointense lesions seen in T2* Gradient-Recall Echo (GRE) and Susceptibility-Weighted (SWI) Magnetic Resonance Imaging (MRI) sequences, corresponding to areas of hemosiderin breakdown products from prior microscopic hemorrhages. They occur in the setting of impaired small vessel integrity, commonly due to either hypertensive vasculopathy or cerebral amyloid angiopathy. Microbleeds are more prevalent in individuals with Alzheimer's disease (AD) dementia and in those with both ischemic and hemorrhagic stroke. However they are also found in asymptomatic individuals, with increasing prevalence with age, particularly in carriers of the Apolipoprotein (APOE) ε4 allele. Other neuroimaging findings that have been linked with microbleeds include lacunar infarcts and white matter hyperintensities on MRI, and increased cerebral β-amyloid burden using (11)C-PiB Positron Emission Tomography. The presence of microbleeds has been suggested to confer increased risk of incident intracerebral hemorrhage - particularly in the setting of anticoagulation - and of complications of immunotherapy for AD. Prospective data regarding the natural history and sequelae of microbleeds are currently limited, however there is a growing evidence base that will serve to inform clinical decision-making in the future.
What this study adds
Evidence grade: Low
This is a narrative review. This review describes cerebral microbleeds as small lesions from prior microscopic hemorrhages, more prevalent in people with Alzheimer's disease dementia and in carriers of the APOE epsilon-4 allele, with prevalence increasing with age. It notes that microbleeds have been suggested to confer increased risk of intracerebral hemorrhage, particularly with anticoagulation, and of complications of immunotherapy for Alzheimer's disease, while prospective data on their natural history remain limited.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Yates, P. A., Villemagne, V. L., Ellis, K. A., Desmond, P. M., Masters, C. L., & Rowe, C. C. (2014). Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Frontiers in neurology. https://doi.org/10.3389/fneur.2013.00205
Vancouver
Yates PA, Villemagne VL, Ellis KA, Desmond PM, Masters CL, Rowe CC. Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Frontiers in neurology. 2014. doi:10.3389/fneur.2013.00205. PMID: 24432010.
BibTeX
@article{yates2014-24432010,
author = {Yates, P. A. and Villemagne, V. L. and Ellis, K. A. and Desmond, P. M. and Masters, C. L. and Rowe, C. C.},
title = {{Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations}},
journal = {Frontiers in neurology},
year = {2014},
doi = {10.3389/fneur.2013.00205},
pmid = {24432010},
url = {https://doi.org/10.3389/fneur.2013.00205}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The presence of microbleeds has been suggested to confer increased risk of incident intracerebral hemorrhage - particularly in the setting of anticoagulation - and of complications of immunotherapy for AD.
Why it matters
This review describes cerebral microbleeds as small lesions from prior microscopic hemorrhages, more prevalent in people with Alzheimer's disease dementia and in carriers of the APOE epsilon-4 allele, with prevalence increasing with age. It notes that microbleeds have been suggested to confer increased risk of intracerebral hemorrhage, particularly with anticoagulation, and of complications of immunotherapy for Alzheimer's disease, while prospective data on their natural history remain limited.
New to this subject? Start with our plain-English guide: Caregiving →
Study details
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in neurology) |
| Journal's citation record | 2 / 4 | Frontiers in Neurology: journal h-index 162 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 232 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 16.6 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 4 / 6 | Cited 17.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 28 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Christopher Cleon Rowe: h-index 100 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Melbourne: institution h-index 1,342 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24432010) |
| Free to read | 2 / 2 | Free to read |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fneur.2013.00205
- PubMed: 24432010
- Original source →
- Free full text: Frontiers in Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Caregiving from nearby years
Also tagged “small”
900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.